LSL.V LSL Pharma Group Inc.
- Market cap
- CAD 39.3M
- P/E
- -
- P/B
- 1.79x
- ROE
- -46.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is LSL.V undervalued?
Graham numberThe Graham number of LSL Pharma Group Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
LSL Pharma Group Inc. fundamental analysis
No fundamental analysis for LSL Pharma Group Inc. yet.
LSL Pharma Group Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About LSL Pharma Group Inc.
LSL Pharma Group Inc. develops, manufactures, and commercializes sterile pharmaceutical products, cosmetic products, and natural health products in Canada, the United States, and internationally. It offers dietary supplements and vitamins in the tablet and capsule form; niche sterile ophthalmic products in the form of ointments and drops; and cosmetic, pharmaceutical, as well as natural health products in sachets, capsules, loose powder, blister packs, and liquids for pharma…
Full company profileLSL Pharma Group Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
LSL Pharma Group Inc. annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 4.82M | 8.77M | 8.21M | 10.0M | 17.7M | 28.7M | 53.9M |
| Gross Profit | 508K | 2.53M | -2.17M | 1.65M | 5.35M | 5.10M | 5.03M |
| Operating Income | 809K | -65.3K | -6.76M | -4.12M | 406K | -2.31M | -5.87M |
| EBITDA | - | - | -5.75M | -5.77M | 6.62M | 2.29M | -2.32M |
| Net Income | 88.0K | -1.78M | -8.06M | -8.47M | 3.32M | -2.82M | -10.1M |
| EPS | 0.00 | -0.02 | -0.10 | -0.10 | 0.03 | -0.02 | -0.08 |
| Balance Sheet | |||||||
| Total Assets | 23.8M | 29.0M | 27.3M | 30.9M | 53.6M | 74.7M | 87.1M |
| Total Liabilities | 16.3M | 17.9M | 22.0M | 22.2M | 28.7M | 47.8M | 65.1M |
| Shareholders' Equity | 7.48M | 11.1M | 5.29M | 8.66M | 24.9M | 27.0M | 22.0M |
| Cash & Short-term Investments | 462K | 741K | 0.00 | 8.00K | 296K | 548K | 967K |
| Cash Flow | |||||||
| Operating Cash Flow | -118K | -1.08M | -3.16M | -7.07M | -1.65M | -2.45M | -4.82M |
| Capital Expenditure | 85.5K | 915K | 997K | 1.02M | 4.20M | 4.96M | 4.33M |
| Free Cash Flow | -203K | -2.00M | -4.16M | -8.09M | -5.85M | -7.40M | -9.15M |
| Ratios | |||||||
| ROE | 1.2% | -16.0% | -152.4% | -97.9% | 13.3% | -10.5% | -46.0% |
| ROA | 0.4% | -6.1% | -29.5% | -27.4% | 6.2% | -3.8% | -11.6% |
| Net Profit Margin | 1.8% | -20.3% | -98.1% | -84.5% | 18.7% | -9.8% | -18.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
LSL Pharma Group Inc. dividends
LSL Pharma Group Inc. has not paid dividends in the last 6 fiscal years.
Who owns LSL Pharma Group Inc.
- Insiders 24.64%
- Institutions 0.00%
- Public & others 75.36%
- Shares outstanding 127M
- Free float 95.7M
LSL Pharma Group Inc. company profile
- Company name
- LSL Pharma Group Inc.
- Ticker
- LSL.V
- Exchange
- TSX Venture Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 252
- Fiscal year end
- December
- Address
- 540, d?Avaugour Street, Boucherville, QC, Canada, J4B 0G6
- Phone
- 514-664-7700
- Website
- groupelslpharma.com
About LSL Pharma Group Inc.
LSL Pharma Group Inc. develops, manufactures, and commercializes sterile pharmaceutical products, cosmetic products, and natural health products in Canada, the United States, and internationally. It offers dietary supplements and vitamins in the tablet and capsule form; niche sterile ophthalmic products in the form of ointments and drops; and cosmetic, pharmaceutical, as well as natural health products in sachets, capsules, loose powder, blister packs, and liquids for pharmacy banners and hospitals. The company is headquartered in Boucherville, Canada.
LSL Pharma Group Inc. management
4- Mr. Francois RobergePresident, CEO & Director · born 1965
- Marc BoudreaultVice-President of Communications
- Mr. Alain R. DugalCOO & Executive VP
- Mr. Guy Paul AllardVice President, Legal Affairs & Corporate Secretary